Swiss drugmaker Novartis and drug developer Monte Rosa Therapeutics agreed to an up to $5.7 billion licensing deal to develop ...

Investors in Novartis (Symbol: NVS) saw new options become available today, for the September 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the NVS options ...

Novartis has agreed to partner on developing additional molecular glue degraders (MGDs) for immune-mediated diseases, in an expanded collaboration that could generate more than $5.7 billion for the ...

Investors in Novartis (Symbol: NVS) saw new options begin trading today, for the February 2025 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the NVS options chain ...

Monte Rosa Therapeutics (NASDAQ:GLUE) shares surged in premarket trading Monday, climbing 65.3% to $7.94 after the biotech ...

In particular, Aradhye noted "increasing progress" at all levels of the innovation supply chain in China — "whether it's ...

Swiss drugmaker Novartis has signed an up to $5.2 billion licensing and options deal with Argo Biopharmaceutical for its ...

(RTTNews) - Novartis (NVS) announced that the U.S. Food and Drug Administration has granted accelerated approval for Fabhalta (iptacopan), a first-in-class complement inhibitor for the reduction of ...

The company states: “Novartis (NVS) announced that oral Fabhalta, iptacopan, has received U.S. Food and Drug Administration approval for the treatment of adults with C3 glomerulopathy, to reduce ...

Swiss drugmaker Novartis and drug developer Monte Rosa Therapeutics signed a licensing deal worth up to US$5.7 billion on Monday to develop drugs for immune-mediated diseases.